Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Old video misrepresented as senior Sri Lankan ruling party member criticising president over fuel shortage - 2Israel and Lebanon's Hezbollah continue to trade attacks
- 3More parents refusing vitamin K shots for newborns, study finds
- 4Flu season is ramping up, and some experts are "pretty worried"
- 5Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- What we know about the 'Stranger Things' spinoff — plus the one cast member who guessed it correctly
- Lego's $650 Pokémon set is already sold out as demand, preorders surge
- Nine in 10 German industrial firms expect Iran war to hit business
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- Analysis-NASA's moon mission tests aerospace old guard as SpaceX, Blue Origin hover
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Council removes proposal to rename park named after former president of Israel
- Aspect Biosystems receives funding for cellular medicine project
